Evidence map›Paper›PMID 34982402›Full record

ReviewWorld journal of pediatrics : WJP2022

Clinical practice guidelines in multisystem inflammatory syndrome (MIS-C) related to COVID-19: a critical review and recommendations.

Alanood S Algarni, Njoud M Alamri, Noor Z Khayat, Raghad A Alabdali, Rawabi S Alsubhi, Shahad H Alghamdi

Abstract readComparative StudyReview
In one paragraph

Review in World journal of pediatrics : WJP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. MIS-C: Diagnosis, Management, and Outcomes.Open forum infectious diseases · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Treatment of multisystem inflammatory syndrome in children.World journal of pediatrics : WJP · 2024
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alanood S AlgarniDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Pharmacy Collage, Umm Al-Qura University, Makkah, 21955, Saudi Arabia. aagarni@uqu.edu.sa.ORCID 0000-0002-2021-8731
Njoud M AlamriPharmacy Collage, Umm Al-Qura University, Makkah, Saudi Arabia.
Noor Z KhayatPharmacy Collage, Umm Al-Qura University, Makkah, Saudi Arabia.
Raghad A AlabdaliPharmacy Collage, Umm Al-Qura University, Makkah, Saudi Arabia.
Rawabi S AlsubhiPharmacy Collage, Umm Al-Qura University, Makkah, Saudi Arabia.
Shahad H AlghamdiPharmacy Collage, Umm Al-Qura University, Makkah, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultisystem inflammatory syndrome in children (MIS-C) is a serious health condition that develops from and is linked to coronavirus disease 2019. MIS-C is considered a multi-organ dysfunction involving cardiac, renal, respiratory, hematologic, gastrointestinal and neurological symptoms and groups of signs and symptoms such as rash or bilateral non-purulent conjunctivitis, hypotension or shock and acute gastrointestinal problems, which require immediate therapeutic intervention to prevent the aggravation of the patient's health condition. MIS-C is relatively new in the field of evidence-based medicine; however, there are several clinical guidelines for good clinical practice. For every disorder, the guidelines have different suggestions. Hence, based on the current status of the evidence, recommendations have been combined to form a unified guideline for therapeutic management.

methodsThis paper compares and evaluates the current MIS-C-specific clinical practice guidelines (namely, American Academy of Pediatrics, American College of Rheumatology, Helen DeVos Children's Hospital Foundation, Children's Hospital of The King's Daughters, and the Infectious Diseases Society of America). The compiled literature was then assessed by the authors separately, and an algorithm was proposed for each disorder, taking into consideration the various guidelines proposed for the management of the disorder.

resultsThe features of MIS-C patients are unified; this is very helpful in managing its symptoms and decreasing mortality rates. In addition, recommendations for pharmacological treatment for MIS-C symptoms are formulated after cross-comparison across five different guidelines.

conclusionsThis study provides a general interpretation of the results in the context of other evidence and implications for future research. It proposes a unified guideline based on the current evidence, with the best potential to maintain suitable clinical standards in the Saudi Arabian Ministry of Health.

Indexed as

COVID-19ChildGastrointestinal DiseasesHumansPractice Guidelines as TopicSARS-CoV-2Saudi ArabiaSystemic Inflammatory Response SyndromeCoronavirus disease 2019Multisystem inflammatory syndromePediatric multisystem inflammatory syndrome

Identifiers

PMID34982402
PMCPMC8725428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.